Our focus is on tackling upstream drivers of chronic inflammation through a disease-modifying therapeutic vaccine approach, beginning with periodontitis and its broader systemic implications.
With important clinical milestones ahead, we’re entering a year of focused execution and value inflection.
Denteric’s CEO Sean McLoughlin looks forward to connecting with those interested in learning more in 2026